Base de dados : MEDLINE
Pesquisa : D06.472.699.631.692.781.400 [Categoria DeCS]
Referências encontradas : 1386 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 139 ir para página                         

  1 / 1386 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28370090
[Au] Autor:Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
[Ad] Endereço:Department of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
[Ti] Título:Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
[So] Source:Aliment Pharmacol Ther;45(11):1390-1402, 2017 Jun.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The goal of hepatorenal syndrome type 1 (HRS-1) treatment is to improve renal function. Terlipressin, a synthetic vasopressin analogue, is a systemic vasoconstrictor used for the treatment of HRS-1, where it is available. AIM: To compare the efficacy of terlipressin plus albumin vs. placebo plus albumin in patients with HRS-1. METHODS: Pooled patient-level data from two large phase 3, randomised, placebo-controlled studies were analysed for HRS reversal [serum creatinine (SCr) value ≤133 µmol/L], 90-day survival, need for renal replacement therapy and predictors of HRS reversal. Patients received intravenous terlipressin 1-2 mg every 6 hours plus albumin or placebo plus albumin up to 14 days. RESULTS: The pooled analysis comprised 308 patients (terlipressin: n = 153; placebo: n = 155). HRS reversal was significantly more frequent with terlipressin vs. placebo (27% vs. 14%; P = 0.004). Terlipressin was associated with a more significant improvement in renal function from baseline until end of treatment, with a mean between-group difference in SCr concentration of -53.0 µmol/L (P < 0.0001). Lower SCr, lower mean arterial pressure and lower total bilirubin and absence of known precipitating factors for HRS were independent predictors of HRS reversal and longer survival in terlipressin-treated patients. CONCLUSIONS: Terlipressin plus albumin resulted in a significantly higher rate of HRS reversal vs. albumin alone in patients with HRS-1. Terlipressin treatment is associated with improved renal function. (ClinicalTrials.gov identifier: OT-0401, NCT00089570; REVERSE, NCT01143246).
[Mh] Termos MeSH primário: Albuminas/uso terapêutico
Síndrome Hepatorrenal/tratamento farmacológico
Lipressina/análogos & derivados
Vasoconstritores/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Ensaios Clínicos Fase III como Assunto
Quimioterapia Combinada
Feminino
Seres Humanos
Lipressina/uso terapêutico
Masculino
Meia-Idade
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Albumins); 0 (Vasoconstrictor Agents); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1111/apt.14052


  2 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28161219
[Au] Autor:Ragot C; Gerbaud E; Boyer A
[Ad] Endereço:Service de Réanimation Médicale, CHU Bordeaux, Bordeaux, France.
[Ti] Título:Terlipressin in refractory shock induced by diltiazem poisoning.
[So] Source:Am J Emerg Med;35(7):1032.e1-1032.e2, 2017 Jul.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Poisoning caused by calcium-channels blockers (CCB) can cause refractory vasoplegic shock, resulting in multiple-organ failure and death despite maximal therapy including high doses of vasopressors. We report one CCB-induced refractory shock complicated with lactate acidosis despite very high doses of epinephrine and norepinephrine. The hemodynamic status of the patient dramatically improved after intermittent boluses of terlipressin, which corrected the acidosis.
[Mh] Termos MeSH primário: Bloqueadores dos Canais de Cálcio/envenenamento
Cuidados Críticos
Diltiazem/envenenamento
Overdose de Drogas/tratamento farmacológico
Lipressina/análogos & derivados
Insuficiência de Múltiplos Órgãos/induzido quimicamente
Vasoconstritores/uso terapêutico
[Mh] Termos MeSH secundário: Diltiazem/uso terapêutico
Overdose de Drogas/complicações
Feminino
Seres Humanos
Lipressina/uso terapêutico
Meia-Idade
Insuficiência de Múltiplos Órgãos/tratamento farmacológico
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Calcium Channel Blockers); 0 (Vasoconstrictor Agents); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin); EE92BBP03H (Diltiazem)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170206
[St] Status:MEDLINE


  3 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28052382
[Au] Autor:Gifford FJ; Morling JR; Fallowfield JA
[Ad] Endereço:Department of Hepatology, Royal Infirmary of Edinburgh, Edinburgh, UK.
[Ti] Título:Systematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.
[So] Source:Aliment Pharmacol Ther;45(5):593-603, 2017 Mar.
[Is] ISSN:1365-2036
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Hepatorenal syndrome type 1 (HRS1) is a functional, rapidly progressive, potentially reversible form of acute kidney injury occurring in patients with cirrhosis. Characterised by intense renal arterial vasoconstriction, it carries a very poor prognosis. There is a significant unmet need for a widely approved, safe and effective pharmacological treatment. AIM: To re-evaluate efficacy and safety of pharmacological treatments for HRS1, in the light of recently published randomised controlled trials (RCTs). METHODS: MEDLINE (OvidSP), EMBASE, PubMed and Cochrane registers were searched for RCTs reporting efficacy and adverse events related to pharmacological treatment of HRS1. Search terms included: 'hepatorenal syndrome', 'terlipressin', 'noradrenaline', 'octreotide', 'midodrine', 'vasopressin', 'dopamine', 'albumin' and synonyms. Comparison of vasoactive drugs vs. placebo/no treatment, and two active drugs were included. Meta-analysis was performed for HRS1 reversal, creatinine improvement, mortality and adverse events. RESULTS: Twelve RCTs enrolling 700 HRS1 patients were included. Treatment with terlipressin and albumin led to HRS1 reversal more frequently than albumin alone or placebo (RR: 2.54, 95% CI: 1.51-4.26). Noradrenaline was effective in reversing HRS1, but trials were small and nonblinded. Overall, there was mortality benefit with terlipressin (RR: 0.79, 95% CI: 0.63-1.01), but sensitivity analysis including only trials with low risk of selection bias weakened this relationship (RR: 0.87, 95% CI: 0.71-1.06). Notably, there was a significant risk of adverse events with terlipressin therapy (RR: 4.32, 95% CI: 0.75-24.86). CONCLUSIONS: Terlipressin treatment is superior to placebo for achieving HRS1 reversal, but mortality benefit is less clear. Terlipressin is associated with significant adverse events, but infusion regimens may be better tolerated. There is continued need for safe and effective treatment options for hepatorenal syndrome.
[Mh] Termos MeSH primário: Síndrome Hepatorrenal/tratamento farmacológico
Cirrose Hepática/tratamento farmacológico
Vasoconstritores/uso terapêutico
[Mh] Termos MeSH secundário: Albuminas/uso terapêutico
Creatinina/metabolismo
Seres Humanos
Lipressina/análogos & derivados
Lipressina/uso terapêutico
Prognóstico
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Albumins); 0 (Vasoconstrictor Agents); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170105
[St] Status:MEDLINE
[do] DOI:10.1111/apt.13912


  4 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27766555
[Au] Autor:Michel J; Hofbeck M; Spiller G; Renk H; Kumpf M; Neunhoeffer F
[Ad] Endereço:Department of Pediatric Cardiology, Pulmology and Pediatric Intensive Care Medicine, University Children's Hospital, Hoppe-Seyler-Str. 1, 72076, Tuebingen, Germany. joerg.michel@med.uni-tuebingen.de.
[Ti] Título:Safety and Efficacy of Terlipressin in Pediatric Distributive Shock: A Retrospective Analysis in 20 Children.
[So] Source:Paediatr Drugs;19(1):35-41, 2017 Feb.
[Is] ISSN:1179-2019
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Data are still lacking about the use of terlipressin or vasopressin in the treatment of pediatric patients who are in a state of therapy-refractory shock. OBJECTIVE: The aim of this study was to evaluate the effect of terlipressin on hemodynamics in children with distributive shock and to describe any severe side effects. METHODS: Consecutive patients (n = 20) with catecholamine-resistant distributive shock who were treated with terlipressin were retrospectively enrolled in this study. We analyzed response in terms of mean arterial blood pressure, heart rate, vasoactive inotropic score (VIS), urinary output, and serum lactate. RESULTS: The hemodynamics of 12 children significantly improved within 6 h of commencing terlipressin (mean blood pressure increase of ≥20 % without VIS increase, or mean blood pressure increase of ≥10 % with VIS decrease of ≥10 %). The hemodynamics of eight patients did not improve, regardless of treatment dosage or duration. More children died in the responders group (n = 7 [58.3 %]) than in the non-responders group (n = 2 [25.0 %]), but this was not statistically significant. Two patients (one in each group) who received high dosages of terlipressin developed rhabdomyolysis. One case of Takotsubo cardiomyopathy was observed, which could be related to terlipressin. CONCLUSIONS: Although treatment with terlipressin resulted in rapid positive hemodynamic responses in some children, it did not seem to have a positive effect in other pediatric patients. Therefore, the possible benefits of terlipressin should be always weighed against potential severe adverse effects.
[Mh] Termos MeSH primário: Lipressina/análogos & derivados
Choque/tratamento farmacológico
Vasoconstritores/uso terapêutico
[Mh] Termos MeSH secundário: Adolescente
Catecolaminas/uso terapêutico
Criança
Pré-Escolar
Feminino
Frequência Cardíaca/efeitos dos fármacos
Hemodinâmica
Seres Humanos
Hipotensão/tratamento farmacológico
Hipotensão/fisiopatologia
Lactente
Recém-Nascido
Lipressina/efeitos adversos
Lipressina/uso terapêutico
Masculino
Estudos Retrospectivos
Choque/fisiopatologia
Síndrome de Resposta Inflamatória Sistêmica/tratamento farmacológico
Síndrome de Resposta Inflamatória Sistêmica/fisiopatologia
Falha de Tratamento
Vasoconstritores/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Catecholamines); 0 (Vasoconstrictor Agents); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161022
[St] Status:MEDLINE
[do] DOI:10.1007/s40272-016-0199-8


  5 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:27464593
[Au] Autor:Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K; REVERSE Investigators
[Ad] Endereço:Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Electronic address: florence.wong@utoronto.ca.
[Ti] Título:Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
[So] Source:Clin Gastroenterol Hepatol;15(2):266-272.e1, 2017 02.
[Is] ISSN:1542-7714
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND & AIMS: Patients with systemic inflammatory response syndrome (SIRS) along with decompensated cirrhosis and renal dysfunction have a poor prognosis and a lower response to treatment. We evaluated the effect of SIRS on the response of hepatorenal syndrome type 1 (HRS-1) to terlipressin. METHODS: We performed a retrospective study of data from a trial of the effects of terlipressin (1 mg every 6 hours or placebo with concomitant albumin) in 198 patients with HRS-1, performed at 50 investigational sites in the United States and 2 in Canada from October 2010 through February 2013. We identified patients with 2 or more criteria for SIRS, without untreated infections (28 received terlipressin and 30 received placebo), and patients with less than 2 criteria for SIRS (control subjects). Primary endpoints included HRS reversal (a decrease in serum level of creatinine to ≤1.5 mg/dL), confirmed HRS reversal (defined as 2 serum creatinine levels ≤1.5 mg/dL, ≥ 48 hours apart), and survival for 90 days after treatment. RESULTS: Baseline characteristics were similar between groups, apart from slightly higher white blood cell counts and heart rates, and slightly lower serum levels of bicarbonate in patients with SIRS versus without SIRS. HRS was reversed in 42.9% of patients who received terlipressin with SIRS (12/28) versus 6.7% of patients who received placebo (2/30) (P = .0018); confirmed HRS reversal occurred in 32.1% of patients who received terlipressin with SIRS (9/28) versus 3.3% who received placebo (1/30) (P = .0048). A larger proportion of patients with SIRS who received terlipressin survived for 90 days without a transplant (13/28; 46.4%) than patients with SIRS who received placebo (7/30; 23.3%) (P = .076). CONCLUSIONS: In an analysis of data from a placebo-controlled study, we found that terlipressin improved renal function and reversed HRS in a higher proportion of patients with HRS-1 and SIRS than patients who received albumin plus placebo. ClincialTrials.gov, number NCT 01143246.
[Mh] Termos MeSH primário: Síndrome Hepatorrenal/tratamento farmacológico
Lipressina/análogos & derivados
Síndrome de Resposta Inflamatória Sistêmica/tratamento farmacológico
Vasoconstritores/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Canadá
Feminino
Síndrome Hepatorrenal/complicações
Seres Humanos
Lipressina/uso terapêutico
Masculino
Meia-Idade
Placebos/administração & dosagem
Estudos Retrospectivos
Análise de Sobrevida
Síndrome de Resposta Inflamatória Sistêmica/complicações
Resultado do Tratamento
Estados Unidos
[Pt] Tipo de publicação:CONTROLLED CLINICAL TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Placebos); 0 (Vasoconstrictor Agents); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160729
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE


  6 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27932181
[Au] Autor:Won YJ; Lim BG; Chung D; Park E; Kim H; Lee IO; Kong MH
[Ad] Endereço:Department of Anesthesiology and Pain Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
[Ti] Título:Use of Terlipressin in an Elderly Patient With Moderate Aortic Valve Stenosis Accompanied by Episodic Atrial Fibrillation During Liver Transplantation: A Case Report.
[So] Source:Transplant Proc;48(9):3203-3206, 2016 Nov.
[Is] ISSN:1873-2623
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Anesthesia for patients with moderate aortic stenosis accompanied by atrial fibrillation during high-risk surgery such as liver transplantation remains a challenge in maintaining control of heart rate and maintenance of cardiac output. The action of terlipressin on vasopressin receptors (mainly V1 receptors) leads to splanchnic vasoconstriction and is the key mechanism responsible for increasing systemic vascular resistance and reducing heart rate. We report successful anesthetic management using low-dose terlipressin infusion in an elderly patient who had moderate aortic stenosis with atrial fibrillation during urgent deceased-donor liver transplantation.
[Mh] Termos MeSH primário: Anestésicos/uso terapêutico
Estenose da Valva Aórtica/complicações
Fibrilação Atrial/complicações
Transplante de Fígado/métodos
Lipressina/análogos & derivados
[Mh] Termos MeSH secundário: Idoso
Feminino
Seres Humanos
Lipressina/uso terapêutico
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anesthetics); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161210
[St] Status:MEDLINE


  7 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27871159
[Au] Autor:Kim SM; Song IH
[Ad] Endereço:Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
[Ti] Título:[Acute Kidney Injury in Cirrhotic Patients with Portal Hypertension].
[So] Source:Korean J Gastroenterol;68(5):237-244, 2016 Nov 25.
[Is] ISSN:2233-6869
[Cp] País de publicação:Korea (South)
[La] Idioma:kor
[Ab] Resumo:Acute kidney injury (AKI) is one of the most common manifestations encountered in clinical practice. It is associated with high morbidity and mortality in cirrhotic pre- and post-transplantation patients. Hepatorenal syndrome (HRS), a special form of AKI in cirrhotic patients, was recognized as a consequence of renal vasoconstriction from systemic/renal hemodynamic alterations developed in advanced cirrhosis with portal hypertension. Recently, multiple factors-such as infection/inflammation, underlying glomerulonephritis, bile cast, or increased abdominal pressure-have been considered to contribute to renal dysfunction in cirrhotic patients, which were presumed to induce HRS. Moreover, in addition to changing the definition of AKI in the nephrologic guidelines, the new AKI definition for early diagnosis and intervention based on characteristics of liver cirrhosis has been proposed in an international meeting. This article provides a comprehensive and recent review of AKI definition, laying out the topics in accordance with the pathophysiologic mechanisms and therapeutic interventions of AKI in cirrhotic patients with portal hypertension.
[Mh] Termos MeSH primário: Lesão Renal Aguda/diagnóstico
Hipertensão Portal/patologia
Cirrose Hepática/patologia
[Mh] Termos MeSH secundário: Lesão Renal Aguda/etiologia
Lesão Renal Aguda/terapia
Biomarcadores/sangue
Creatinina/sangue
Seres Humanos
Hipertensão Portal/complicações
Transplante de Rim
Cirrose Hepática/complicações
Lipressina/análogos & derivados
Lipressina/uso terapêutico
Albumina Sérica/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers); 0 (Serum Albumin); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin); AYI8EX34EU (Creatinine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161123
[St] Status:MEDLINE
[do] DOI:10.4166/kjg.2016.68.5.237


  8 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27824220
[Au] Autor:Khandelwal A; Gupta D; Haldar R; Rai A
[Ad] Endereço:Department of Anaesthesiology, Sanjay Gandhi Post Graduate Institute Of Medical Sciences (Sgpgims), Lucknow, Uttar Pradesh, India. ankurchintus@gmail.com.
[Ti] Título:Isolated lower limb gangrene: a caveat of terlipressin therapy.
[So] Source:Anaesthesiol Intensive Ther;48(5):370-372, 2016.
[Is] ISSN:1731-2515
[Cp] País de publicação:Poland
[La] Idioma:eng
[Mh] Termos MeSH primário: Gangrena/etiologia
Extremidade Inferior
Lipressina/análogos & derivados
Vasoconstritores/efeitos adversos
[Mh] Termos MeSH secundário: Idoso
Seres Humanos
Lipressina/efeitos adversos
Lipressina/uso terapêutico
Masculino
Vasoconstritores/uso terapêutico
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasoconstrictor Agents); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161109
[St] Status:MEDLINE
[do] DOI:10.5603/AIT.a2016.0049


  9 / 1386 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27643543
[Au] Autor:Castellanos-González M; Marzal-Alfaro MB; Díaz-Sánchez A; Martos MG
[Ad] Endereço:Department of Dermatology and Venereology, Hospital del Sureste, Arganda del Rey, Madrid, Spain.
[Ti] Título:Linear IgA bullous dermatosis due to vancomycin and cutaneous necrosis due to terlipressin in the same patient.
[So] Source:Indian J Dermatol Venereol Leprol;82(6):723-726, 2016 Nov-Dec.
[Is] ISSN:0973-3922
[Cp] País de publicação:India
[La] Idioma:eng
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Anti-Hipertensivos/efeitos adversos
Lipressina/análogos & derivados
Dermatopatias/induzido quimicamente
Vancomicina/efeitos adversos
[Mh] Termos MeSH secundário: Seres Humanos
Dermatose Linear Bolhosa por IgA/induzido quimicamente
Lipressina/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antihypertensive Agents); 50-57-7 (Lypressin); 6Q205EH1VU (Vancomycin); 7Z5X49W53P (terlipressin)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160920
[St] Status:MEDLINE
[do] DOI:10.4103/0378-6323.190845


  10 / 1386 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27494726
[Au] Autor:Jao YT
[Ad] Endereço:Department of Cardiology and Critical Care Medicine, Tainan Municipal Hospital, No. 670 Chung De Road, East District, Tainan 701, Taiwan.
[Ti] Título:Refractory torsade de pointes induced by terlipressin (Glypressin).
[So] Source:Int J Cardiol;222:135-40, 2016 Nov 01.
[Is] ISSN:1874-1754
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Antiarrítmicos/administração & dosagem
Varizes Esofágicas e Gástricas
Esofagoscopia/métodos
Hemorragia Gastrointestinal
Lipressina/análogos & derivados
Torsades de Pointes
[Mh] Termos MeSH secundário: Idoso
Coma/etiologia
Cardioversão Elétrica/métodos
Eletrocardiografia/métodos
Varizes Esofágicas e Gástricas/complicações
Varizes Esofágicas e Gástricas/diagnóstico
Varizes Esofágicas e Gástricas/fisiopatologia
Evolução Fatal
Hemorragia Gastrointestinal/diagnóstico
Hemorragia Gastrointestinal/etiologia
Hemorragia Gastrointestinal/terapia
Parada Cardíaca/etiologia
Parada Cardíaca/terapia
Seres Humanos
Lipressina/administração & dosagem
Lipressina/efeitos adversos
Masculino
Marca-Passo Artificial
Recidiva
Síndrome de Romano-Ward/diagnóstico
Síndrome de Romano-Ward/etiologia
Síndrome de Romano-Ward/fisiopatologia
Síndrome de Romano-Ward/terapia
Torsades de Pointes/induzido quimicamente
Torsades de Pointes/diagnóstico
Torsades de Pointes/fisiopatologia
Torsades de Pointes/terapia
Vasoconstritores/administração & dosagem
Vasoconstritores/efeitos adversos
[Pt] Tipo de publicação:CASE REPORTS; LETTER
[Nm] Nome de substância:
0 (Anti-Arrhythmia Agents); 0 (Vasoconstrictor Agents); 50-57-7 (Lypressin); 7Z5X49W53P (terlipressin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171004
[Lr] Data última revisão:
171004
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160806
[St] Status:MEDLINE



página 1 de 139 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde